Clinical Trial Detail

NCT ID NCT03093116
Title A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Turning Point Therapeutics, Inc.
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

Therapies

Repotrectinib

Age Groups: child senior adult

Additional content available in CKB BOOST